Navigation Links
AtheroNova Adds New Medical Advisor
Date:4/11/2013

the American Heart Association.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please visit www.AtheroNova.com.

Forward-Looking Statements

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of AtheroNova's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
2. AtheroNova Names New Director
3. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
4. AtheroNova Releases 2011 Financial Results
5. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
6. AtheroNova Announces a New Board Member
7. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
8. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
9. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
10. “Scientific And Medical Research On The Successful Treatment Of Type 1 + 2 Diabetes With Alkaline Reduced Water” is Reviewed in Today’s Bawell Water Ionizer Health Report
11. Dermatology Associates Medical Group in Beverly Hills Announces Safe, Fast Anti-Aging Laser Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... September 01, 2014 The global ... million by 2019 from $1,070.7 million in 2014, ... to 2019. The global oligonucleotide synthesis market is ... applications, end users, and geography. The synthesized oligonucleotides ... rate in the oligonucleotide synthesis market during the ...
(Date:8/31/2014)... 2014 Market Research Report ... and in-depth research report on the Polyacrylamide ... including Polyacrylamide definition, classification, application, and industry ... This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic ...
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
Breaking Biology Technology:9.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
... /PRNewswire/ -- The Nano Science and Technology Institute ... will take place May 3-7, 2009 at the George R. ... 12th year, the largest and most prominent Nanotechnology event is ... Micro and Bio technology executives, who will gather to promote ...
... CLINTON, N.J., Jan. 8 Ikaria Holdings, Inc. today ... present at the 27th Annual JPMorgan Healthcare Conference on ... The conference will be held January 12-15 at The ... Holdings, Inc. , Ikaria Holdings, Inc. is a ...
... /PRNewswire/ - Aegera Therapeutics Inc. announced today the ... Phase 2 study of AEG35156, their targeted antisense ... , The study, entitled "A Phase 2, Multicenter, ... Apoptosis (XIAP) Antisense AEG35156 Given In Combination With ...
Cached Biology Technology:NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 2NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 3NSTI Announces the 12th Annual Nanotech Conference & Expo 2009 May 3-7, at the George R. Brown Convention Center in Houston, Texas 4Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference 2Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer 2
(Date:9/1/2014)... after birth, every child in the U.S. undergoes a ... conditions, including sickle cell disease. Thousands of children born ... many suffer and die from the disease each year. ... to at least some of those deaths. , ... in the lab of George Whitesides, the Woodford L. ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
(Date:9/1/2014)... to a life without light. They emit echolocation sounds and ... to obstacles or prey. In their brains, they have a ... by researchers at Technische Universitt Mnchen (TUM) has shown for ... factors. , Closer objects appear larger ... object, the number of activated neurons in its brain increases. ...
Breaking Biology News(10 mins):Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3A nucleotide change could initiate fragile X syndrome 2Zooming in for a safe flight 2
... June 1, 2010 -- The National Oceanic and Atmospheric ... of Miami (UM) to continue to lead its partnership ... (CIMAS). NOAA and UM scientists have worked ... of climate, hurricanes, and marine ecosystems along the southeastern ...
... Since the 1990s, a green fluorescent protein known simply as ... Northwest jellyfish, GFP allows scientists to visualize proteins inside of ... Two years ago, biologists who discovered and developed the protein ... work. However, using GFP as a fluorescent probe has ...
... viable due to aberrant chromosome distribution if they had ... German Cancer Research Center have investigated which genes are ... revealed that cancer cells rely on the tension ... Thus, proteins which maintain this tension are promising targets ...
Cached Biology News:NOAA selects University of Miami to lead major southeastern US cooperative institute 2NOAA selects University of Miami to lead major southeastern US cooperative institute 3MIT chemists design new way to fluorescently label proteins 2No relaxing for cancer cells 2
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... Major Science Smart Minis 150V power supply ... mini power supplies designed to meet most ... to use unit. The Minis 150V power ... The Minis Power Supply is designed for ...
Biology Products: